Aquinox Pharmaceuticals Company Profile (NASDAQ:AQXP)

About Aquinox Pharmaceuticals (NASDAQ:AQXP)

Aquinox Pharmaceuticals logoAquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company's primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway. Its product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. The Company is developing AQX-1125 as a treatment in interstitial cystitis/bladder pain syndrome (IC/BPS), a chronic inflammatory disease of the bladder. AQX-1125 is a SHIP1 activator that has demonstrated preliminary safety, anti-inflammatory potential and drug properties in multiple preclinical studies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:AQXP
  • CUSIP: N/A
  • Web: www.aqxpharma.com
Capitalization:
  • Market Cap: $322.63 million
  • Outstanding Shares: 23,464,000
Average Prices:
  • 50 Day Moving Avg: $14.27
  • 200 Day Moving Avg: $14.66
  • 52 Week Range: $9.83 - $19.97
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.17
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $5.31 per share
  • Price / Book: 2.59
Profitability:
  • Return on Equity: -29.54%
  • Return on Assets: -27.88%
Debt:
  • Current Ratio: 16.28%
  • Quick Ratio: 16.28%
Misc:
  • Average Volume: 68,069 shs.
  • Beta: -16.98
  • Short Ratio: 20.45
 

Frequently Asked Questions for Aquinox Pharmaceuticals (NASDAQ:AQXP)

What is Aquinox Pharmaceuticals' stock symbol?

Aquinox Pharmaceuticals trades on the NASDAQ under the ticker symbol "AQXP."

How were Aquinox Pharmaceuticals' earnings last quarter?

Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) released its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.59) EPS for the quarter, meeting the consensus estimate of ($0.59). View Aquinox Pharmaceuticals' Earnings History.

When will Aquinox Pharmaceuticals make its next earnings announcement?

Aquinox Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Aquinox Pharmaceuticals.

Where is Aquinox Pharmaceuticals' stock going? Where will Aquinox Pharmaceuticals' stock price be in 2017?

4 equities research analysts have issued 1-year target prices for Aquinox Pharmaceuticals' stock. Their forecasts range from $22.00 to $28.00. On average, they expect Aquinox Pharmaceuticals' stock price to reach $24.67 in the next year. View Analyst Ratings for Aquinox Pharmaceuticals.

Who are some of Aquinox Pharmaceuticals' key competitors?

Who are Aquinox Pharmaceuticals' key executives?

Aquinox Pharmaceuticals' management team includes the folowing people:

  • David J. Main, Co-Founder, President and Chief Executive Officer and Chairman of the Board
  • Kamran Alam, Chief Financial Officer, Vice President - Finance
  • Lloyd Mackenzie, Vice President - Technical Operations and Planning
  • David Chilton Mitchell, Vice President - Global Regulatory Affairs & Quality Assurance
  • Barbara Troupin M.D., Chief Medical Officer, Vice President - Clinical Development
  • Robert E. Pelzer, Lead Independent Director
  • Gary J. Bridger Ph.D., Director
  • Daniel J. Levitt M.D., Ph.D., Director
  • Richard S. Levy M.D., Director
  • Kelvin M. Neu M.D., Director

Who owns Aquinox Pharmaceuticals stock?

Aquinox Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include RA Capital Management LLC (5.96%), Franklin Resources Inc. (5.64%), Goldman Sachs Group Inc. (4.11%), Vanguard Group Inc. (1.21%), Royce & Associates LP (0.62%) and Emory University (0.45%). Company insiders that own Aquinox Pharmaceuticals stock include Bros Advisors Lp Baker and David Main. View Institutional Ownership Trends for Aquinox Pharmaceuticals.

Who sold Aquinox Pharmaceuticals stock? Who is selling Aquinox Pharmaceuticals stock?

Aquinox Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including RA Capital Management LLC, Emory University, Goldman Sachs Group Inc., D.A. Davidson & CO. and ProShare Advisors LLC. View Insider Buying and Selling for Aquinox Pharmaceuticals.

Who bought Aquinox Pharmaceuticals stock? Who is buying Aquinox Pharmaceuticals stock?

Aquinox Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Nexthera Capital LP, Sphera Funds Management LTD., Vanguard Group Inc., Archon Partners LLC, Bank of New York Mellon Corp, Northern Trust Corp and Alps Advisors Inc.. View Insider Buying and Selling for Aquinox Pharmaceuticals.

How do I buy Aquinox Pharmaceuticals stock?

Shares of Aquinox Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aquinox Pharmaceuticals' stock price today?

One share of Aquinox Pharmaceuticals stock can currently be purchased for approximately $13.75.


MarketBeat Community Rating for Aquinox Pharmaceuticals (NASDAQ AQXP)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  149 (Vote Outperform)
Underperform Votes:  82 (Vote Underperform)
Total Votes:  231
MarketBeat's community ratings are surveys of what our community members think about Aquinox Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Aquinox Pharmaceuticals (NASDAQ:AQXP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $24.67 (79.39% upside)

Analysts' Ratings History for Aquinox Pharmaceuticals (NASDAQ:AQXP)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/8/2017Canaccord GenuitySet Price TargetBuy$22.00HighView Rating Details
5/9/2017Cantor FitzgeraldSet Price TargetBuy$28.00LowView Rating Details
11/11/2016Leerink SwannReiterated RatingBuy$24.00N/AView Rating Details
11/10/2016Needham & Company LLCReiterated RatingBuyN/AView Rating Details
8/5/2016Jefferies Group LLCBoost Price TargetHold$7.00 -> $9.00N/AView Rating Details
11/3/2015Cowen and CompanyReiterated RatingBuy$23.00N/AView Rating Details
10/6/2015GuggenheimInitiated CoverageBuy$22.00N/AView Rating Details
(Data available from 9/24/2015 forward)

Earnings

Earnings History for Aquinox Pharmaceuticals (NASDAQ:AQXP)
Earnings by Quarter for Aquinox Pharmaceuticals (NASDAQ:AQXP)
Earnings History by Quarter for Aquinox Pharmaceuticals (NASDAQ AQXP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($0.59)N/AView Earnings Details
8/8/20176/30/2017($0.59)($0.59)ViewListenView Earnings Details
5/9/20173/31/2017($0.51)($0.36)ViewN/AView Earnings Details
3/9/201712/31/2016($0.51)($0.48)ViewListenView Earnings Details
11/9/2016Q316($0.58)($0.46)ViewN/AView Earnings Details
8/4/2016Q2($0.41)($0.63)ViewN/AView Earnings Details
5/10/2016Q1($0.35)($0.39)ViewN/AView Earnings Details
11/10/2015Q315($0.45)($0.43)ViewN/AView Earnings Details
8/6/2015Q215($0.56)($0.44)ViewN/AView Earnings Details
5/12/2015Q115($0.83)($0.60)ViewN/AView Earnings Details
4/15/2015($0.57)($0.78)ViewN/AView Earnings Details
3/16/2015Q4 2014($0.76)($0.78)ViewN/AView Earnings Details
11/4/2014Q3 2014($0.29)($0.59)ViewN/AView Earnings Details
8/11/2014Q2 2014($0.27)($0.51)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aquinox Pharmaceuticals (NASDAQ:AQXP)
2017 EPS Consensus Estimate: ($2.43)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.57)($0.57)($0.57)
Q2 20171($0.59)($0.59)($0.59)
Q3 20171($0.62)($0.62)($0.62)
Q4 20171($0.65)($0.65)($0.65)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Aquinox Pharmaceuticals (NASDAQ:AQXP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Aquinox Pharmaceuticals (NASDAQ:AQXP)
Insider Ownership Percentage: 2.70%
Institutional Ownership Percentage: 95.15%
Insider Trades by Quarter for Aquinox Pharmaceuticals (NASDAQ:AQXP)
Institutional Ownership by Quarter for Aquinox Pharmaceuticals (NASDAQ:AQXP)
Insider Trades by Quarter for Aquinox Pharmaceuticals (NASDAQ:AQXP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/5/2017David MainInsiderSell15,625$13.26$207,187.50View SEC Filing  
1/9/2017Bros. Advisors Lp BakerMajor ShareholderBuy398,062$17.18$6,838,705.16View SEC Filing  
9/20/2016Bros. Advisors Lp BakerMajor ShareholderBuy2,783,605$12.25$34,099,161.25View SEC Filing  
3/16/2016Bros. Advisors Lp BakerMajor ShareholderBuy471,667$7.99$3,768,619.33View SEC Filing  
3/15/2016Bros. Advisors Lp BakerMajor ShareholderBuy109,912$7.98$877,097.76View SEC Filing  
1/26/2016Bros. Advisors Lp BakerMajor ShareholderBuy140,786$10.80$1,520,488.80View SEC Filing  
1/20/2016Bros. Advisors Lp BakerMajor ShareholderBuy112,034$9.48$1,062,082.32View SEC Filing  
1/19/2016Bros. Advisors Lp BakerMajor ShareholderBuy78,045$9.11$710,989.95View SEC Filing  
1/15/2016Bros. Advisors Lp BakerMajor ShareholderBuy202,623$8.28$1,677,718.44View SEC Filing  
9/10/2015Bros. Advisors Lp BakerMajor ShareholderBuy2,480,032$15.50$38,440,496.00View SEC Filing  
8/24/2015David Chilton MitchellVPBuy3,575$17.81$63,670.75View SEC Filing  
8/12/2015Kamran AlamCFOSell29,079$18.67$542,904.93View SEC Filing  
8/12/2015Lloyd MackenzieVPSell35,887$18.67$670,010.29View SEC Filing  
12/17/2014& Johnson JohnsonMajor ShareholderSell8,100$7.62$61,722.00View SEC Filing  
12/12/2014& Johnson JohnsonMajor ShareholderSell5,000$7.51$37,550.00View SEC Filing  
12/10/2014& Johnson JohnsonMajor ShareholderSell8,300$7.72$64,076.00View SEC Filing  
12/9/2014& Johnson JohnsonMajor ShareholderSell5,000$7.73$38,650.00View SEC Filing  
12/8/2014& Johnson JohnsonMajor ShareholderSell2,000$7.69$15,380.00View SEC Filing  
12/5/2014& Johnson JohnsonMajor ShareholderSell15,900$7.76$123,384.00View SEC Filing  
12/1/2014& Johnson JohnsonMajor ShareholderSell1,200$7.54$9,048.00View SEC Filing  
11/26/2014& Johnson JohnsonMajor ShareholderSell2,000$7.75$15,500.00View SEC Filing  
11/24/2014& Johnson JohnsonMajor ShareholderSell9,500$8.14$77,330.00View SEC Filing  
3/12/2014Pfizer IncMajor ShareholderBuy272,727$11.00$2,999,997.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Aquinox Pharmaceuticals (NASDAQ:AQXP)
Latest Headlines for Aquinox Pharmaceuticals (NASDAQ:AQXP)
Source:
DateHeadline
finance.yahoo.com logoAquinox to Present at 2017 Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 18 at 4:25 PM
americanbankingnews.com logoReviewing Aquinox Pharmaceuticals (AQXP) & Its Peers
www.americanbankingnews.com - September 18 at 4:28 AM
americanbankingnews.com logoAquinox Pharmaceuticals, Inc. (AQXP) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - September 16 at 4:54 PM
americanbankingnews.com logoValuEngine Lowers Aquinox Pharmaceuticals, Inc. (AQXP) to Sell
www.americanbankingnews.com - September 15 at 11:12 PM
seekingalpha.com logoAquinox Pharmaceuticals: Buy, Sell Or Hold? - Seeking Alpha
seekingalpha.com - September 1 at 9:35 PM
globenewswire.com logoAquinox Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome - GlobeNewswire (press release)
globenewswire.com - August 29 at 9:24 PM
streetinsider.com logoAquinox Pharma (AQXP) Issues Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome
www.streetinsider.com - August 29 at 2:07 AM
americanbankingnews.com logoCollegium Pharmaceutical (COLL) and Aquinox Pharmaceuticals (AQXP) Head-To-Head Comparison
www.americanbankingnews.com - August 29 at 12:22 AM
streetinsider.com logoAquinox Pharma (AQXP) Issues Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder ... - StreetInsider.com
www.streetinsider.com - August 28 at 9:07 PM
feeds.benzinga.com logoAquinox Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome
feeds.benzinga.com - August 28 at 9:46 AM
americanbankingnews.com logoAquinox Pharmaceuticals, Inc. (AQXP) Expected to Post Earnings of -$0.62 Per Share
www.americanbankingnews.com - August 23 at 12:20 PM
americanbankingnews.com logoAquinox Pharmaceuticals, Inc. (AQXP) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - August 22 at 4:36 PM
americanbankingnews.com logoDr. Reddy's Laboratories (RDY) versus Aquinox Pharmaceuticals (AQXP) Head-To-Head Contrast
www.americanbankingnews.com - August 22 at 4:16 PM
prnewswire.com logoAnalyzing the Financial Health of Biotech Companies - PR Newswire (press release)
www.prnewswire.com - August 17 at 10:27 PM
americanbankingnews.com logoAquinox Pharmaceuticals, Inc. (AQXP) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - August 15 at 4:52 PM
americanbankingnews.com logoAquinox Pharmaceuticals, Inc. (AQXP) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - August 10 at 4:32 PM
americanbankingnews.com logoFY2017 EPS Estimates for Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Increased by Analyst
www.americanbankingnews.com - August 10 at 1:50 PM
seekingalpha.com logoAquinox Pharmaceuticals' (AQXP) CEO David Main on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 8 at 3:52 PM
globenewswire.com logoAquinox Pharmaceuticals Announces Second Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - August 8 at 3:52 PM
finance.yahoo.com logoInvestor Network: Aquinox Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - August 8 at 3:52 PM
finance.yahoo.com logoAquinox Pharmaceuticals Announces Second Quarter 2017 Financial Results
finance.yahoo.com - August 8 at 3:51 PM
finance.yahoo.com logoAquinox reports 2Q loss
finance.yahoo.com - August 8 at 3:51 PM
americanbankingnews.com logoAquinox Pharmaceuticals, Inc. (AQXP) Issues Earnings Results
www.americanbankingnews.com - August 8 at 2:24 PM
americanbankingnews.com logoAquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Upgraded by BidaskClub to "Hold"
www.americanbankingnews.com - August 6 at 1:56 PM
americanbankingnews.com logoZacks: Brokerages Anticipate Aquinox Pharmaceuticals, Inc. (AQXP) to Post -$0.59 EPS
www.americanbankingnews.com - August 5 at 7:08 AM
finance.yahoo.com logoAquinox to Present at Canaccord Genuity 37th Annual Growth Conference
finance.yahoo.com - August 2 at 4:50 PM
finance.yahoo.com logoAquinox to Present at Canaccord Genuity 37th Annual Growth Conference
finance.yahoo.com - August 2 at 4:50 PM
finance.yahoo.com logoAquinox Pharmaceuticals to Announce Second Quarter 2017 Financial Results
finance.yahoo.com - August 1 at 4:59 PM
americanbankingnews.com logoAquinox Pharmaceuticals, Inc. (AQXP) Cut to "Sell" at BidaskClub
www.americanbankingnews.com - July 29 at 9:21 PM
americanbankingnews.com logoAquinox Pharmaceuticals, Inc. (AQXP) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - July 28 at 4:39 PM
americanbankingnews.com logoAquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) to Release Earnings on Wednesday
www.americanbankingnews.com - July 26 at 7:20 AM
americanbankingnews.com logoAnalyzing Aquinox Pharmaceuticals (AQXP) and Teligent (TLGT)
www.americanbankingnews.com - July 19 at 8:51 AM
americanbankingnews.com logo Brokerages Anticipate Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Will Post Earnings of -$0.59 Per Share
www.americanbankingnews.com - July 13 at 10:20 PM
americanbankingnews.com logoAquinox Pharmaceuticals, Inc. (AQXP) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - July 11 at 5:26 PM
finance.yahoo.com logoCorium International (CORI) Catches Eye: Stock Jumps 11.9%
finance.yahoo.com - July 8 at 6:21 AM
americanbankingnews.com logoAquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 3 at 4:58 PM
americanbankingnews.com logoContrasting Theravance Biopharma (TBPH) and Aquinox Pharmaceuticals (AQXP)
www.americanbankingnews.com - June 26 at 2:26 PM
americanbankingnews.com logo Brokerages Expect Aquinox Pharmaceuticals, Inc. (AQXP) Will Announce Earnings of -$0.59 Per Share
www.americanbankingnews.com - June 19 at 10:28 PM
americanbankingnews.com logoAquinox Pharmaceuticals, Inc. (AQXP) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - June 13 at 1:00 AM
americanbankingnews.com logoAquinox Pharmaceuticals Inc (AQXP) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - June 6 at 2:38 PM
americanbankingnews.com logoInsider Selling: Aquinox Pharmaceuticals Inc (AQXP) Insider Sells 15,625 Shares of Stock
www.americanbankingnews.com - June 5 at 8:07 PM
finance.yahoo.com logoSupernus Pharmaceuticals (SUPN) Jumps: Stock Rises 6.2%
finance.yahoo.com - June 1 at 3:50 PM
finance.yahoo.com logoAquinox to Present at Jefferies 2017 Global Healthcare Conference
finance.yahoo.com - June 1 at 3:50 PM
americanbankingnews.com logoAquinox Pharmaceuticals Inc Forecasted to Earn FY2017 Earnings of ($2.24) Per Share (AQXP)
www.americanbankingnews.com - May 15 at 8:54 AM
americanbankingnews.com logoShort Interest in Aquinox Pharmaceuticals Inc (AQXP) Declines By 19.6%
www.americanbankingnews.com - May 14 at 9:14 AM
americanbankingnews.com logoAquinox Pharmaceuticals Inc (AQXP) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 12 at 2:38 PM
americanbankingnews.com logoAquinox Pharmaceuticals Inc (AQXP) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - May 11 at 10:52 PM
reuters.com logoBRIEF-Aquinox Pharmaceuticals Qtrly loss per share $0.36
www.reuters.com - May 11 at 3:59 PM
americanbankingnews.com logoResearch Analysts Issue Forecasts for Aquinox Pharmaceuticals Inc's FY2017 Earnings (AQXP)
www.americanbankingnews.com - May 11 at 11:42 AM
americanbankingnews.com logoAquinox Pharmaceuticals Inc (AQXP) Given a $28.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - May 9 at 11:36 PM

Social

Chart

Aquinox Pharmaceuticals (AQXP) Chart for Sunday, September, 24, 2017

This page was last updated on 9/24/2017 by MarketBeat.com Staff